Findings shared here were originally presented in a poster session at ACT 2025

Drug development is not for the faint of heart; a twist on the Hunger Games saying, “May the odds be (n)ever in your favor,” might adequately characterizes the challenge. As scientists, however, we manage these inherent risks by establishing best practices and learning from our collective successes and failures, as well as. In this field, experience truly matters.

Nomination of a clinical candidate and subsequent conduct of toxicology studies to support a first-in-human (FIH) clinical trial is an exciting milestone for sponsors! While many are highly experienced drug discovery professionals, some may have limited, or even no experience, in early clinical development, including the critical toxicology studies required to successfully support a FIH trial.

The 76^th annual American Association for Laboratory Animal Science (AALAS) National Meeting is a cornerstone event for the laboratory animal science community, bringing together researchers, veterinarians, technicians, and industry partners to share knowledge, i